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Introduction. Hyperglycemia is a condition in which an excessive amount of glucose 
circulates in the blood plasma and is a common adverse reaction of anabolic steroids therapy, 
affecting 20% to 50% of patients without a history of diabetes. In addition, glucose levels are 
often elevated among patients with prediabetes and previously well-controlled diabetes during 
steroid therapy. Anabolics stimulate glucose production by the liver and inhibit peripheral 
glucose uptake, resulting in insulin resistance allowing blood glucose levels to rise and remain 
higher.  
Aim of the study. To determine the manifestations of hyperglycemia after utilization of 
anabolics.  
Materials and methods. It was made the bibliographic and personal investigations of 
hyperglycemic state due to anabolics. Twenty-five healthy male power athletes were followed 
up during their self-regimen of substance abuse.  
Results. In our investigation, there is determined that more than half of the men receiving high-
dose steroids develop hyperglycemia, with an incidence of 86% of at least one episode of 
hyperglycemia and 41% of athletes presenting a mean blood glucose ≥ 140 mg/dL 
Hyperglycemia incidence in men without a prior history of diabetes mellitus (DM) to steroid 
use varies from 34.3% to 56% for athletes with 1-3 years of anabolic utilization. The 
manifestations of hyperglycemia were: polyuria (36%), polydipsia (29%), polyphagia (41%), 
dizziness (18%), shakiness (19%), irritability or moodiness (37%), anxiety or nervousness 
(26%), trouble concentration (15%). The development of hyperglycemia was observed on 41% 
athletes, 29 - 41 years old, who reported a consumption of AAS for 1-3 years. They self-
administered high doses of oral stanozolol, oxymetholone, methandrostenolone and 
ibutamoren. For management of hyperglycemia, if diet and physical exercise do not reduce the 
glucose levels adequately, it is recommended to prescribe antidiabetic drugs, such as 
metformin, DPP-4 inhibitors or sulfonylureas that are effective and work by increasing insulin 
release from the pancreas but they may cause hypoglycemia.  
Conclusions. Complications associated with steroid-induced hyperglycemia are often 
underestimated despite hyperglycemia being a well-known adverse effect of anabolic therapy. 
Appropriate management of hyperglycemia due to anabolics is oral antidiabetic agent, such as 
a DPP-4 inhibitors, metformin, or by using the weight-based NPH insulin may reduce the risk 
of adverse outcomes, including symptomatic hyperglycemia and new-onset diabetes.  
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Introduction. Thrombophilia is defined as an abnormal coagulation state of blood that 
increases the risk of thrombosis. Pregnancy represents a physiological hypercoagulation state. 
But, women with acquired and hereditary thrombophilia are at increased risk of developing 
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venous thromboembolism and other associated gestational vascular complications like 
Recurrent Pregnancy Loss (RPL), preeclampsia, intrauterine growth restriction, and placental 
abruption during pregnancy. These complications are a major cause of maternal and fetal 
morbidity and mortality.   
Aim of the study.  This study focuses on the women who reported RPL, without any positive 
pregnancy and the identification of genetic factors that lead to the formation of thrombosis (F2 
G20210A, F5 G1691A, MTHFR C677T, MTHFR A1289C, MTR A2756G, MTRR A66G), 
involved in fibrinolysis (PAI-1 4G/5G) and their association with primary female infertility. 
Materials and methods.  Research design was constructed as case-control type. The case 
group was represented by 44 patients with RPL, without any positive pregnancy, with normal 
karyotype, and lack of other causes (intrauterine infections, uterine pathology) responsible for 
the RPL. The control group included 57 patients with 2 positive pregnancies who did not 
receive anticoagulant treatment. The Odds Ratio (OR) was calculated for the case group and 
control group, at a 95% confidence interval, and p values <0,005 were considered statistically 
significant. OR>1 demonstrate a strong association between mutation and RPL, OR<1 show a 
weak association. 
Results. We found that G1691A mutation in F5 gene encoding factor V (Leiden) (for 
heterozygous genotype OR=8,84; 95% CI; 1,02-76,42; p<0,05) and mutation G20210A in gene 
F2 encoding factor II (prothrombin), (for heterozygous genotype OR=7,18; 95% CI; 0,81-
63,87; p<0,05), are major risk factors for RPL and primary female infertility. Carriers of the 
homozygous genotype after mutant allele were not determined in either group. The 4G/5G 
polymorphism of the PAI-1 gene, in this study was not associated with RPL and primary female 
infertility. Analysis of genes involved in folate cycle as MTHFR C677T mutation (OR=3,33; 
95% CI; 1,37-8,09; p<0,05 for the heterozygous genotype and OR=3,73; 95% CI; 0,99-14,05; 
p<0,05 for the homozygous genotype after the mutant allele), MTR mutation A2756G (for the 
heterozygous genotype OR=2,91; 95%CI; 1,19-7,08; p<0,05 and for the homozygous genotype 
after the mutant allele OR=6,30; 95%CI; 1,17-34,03; p<0,05), MTRR mutation A66G (for the 
heterozygous genotype OR=2,40; 95%CI; 1,02-5,62; p<0,05 and for the homozygous genotype 
after the mutant allele OR=5,77; 95%CI; 0,99-33,68; p<0,05),demonstrated that these 
polymorphisms are major risk factors of RPL and primary female infertility. A1289C mutation 
of the MTHFR gene was not associated with RPL and primary female infertility. 
Conclusion. According to the results of the study, it is recommended the genetic diagnosis of 
all patients with RPL, without organic or infectious causes, for detection of the genetic factors 
involved in hereditary thrombophilia. 
Key words: hereditary thrombophilia, recurrent pregnancy loss, primary female infertility   
 
316. CLINICAL AND CYTOGENETIC VARIATIONS IN MALE INFERTILITY 
CAUSED BY KLINEFELTER SYNDROME  
Author: Nicoleta Mironiuc  
Scientific adviser: Stela Racoviță, PhD, University Assistant, Department of Molecular 
Biology and Human Genetics, Nicolae Testemitanu State University of Medicine and 
Pharmacy, Chisinau, Republic of Moldova.  
 
Introduction. Klinefelter’s syndrome (KS) is the most common genetic cause of human male 
infertility characterized by gynecomastia, hypogonadism and azoospermia. About 80–90% of 
patients with Klinefelter's syndrome have an homogenous 47,XXY karyotype, the classic form 
of Klinefelter's syndrome. The prevalence of Klinefelter's syndrome is 1 in 700 men. Many 
patients with Klinefelter syndrome remain undiagnosed due to clinical variations.  
